ENDRA Life Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on November 29, 2022, regarding a special meeting of stockholders held by ENDRA Life Sciences Inc. The company is incorporated in Delaware and trades on The Nasdaq Stock Market under the symbol NDRA.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on corporate governance actions and stockholder voting results.
Material Changes and Voting Results
At the special meeting, stockholders voted on a proposal to amend the Company's Certificate of Incorporation to authorize a reverse stock split. The certified voting results were as follows:
- For: 21,057,265,393 votes
- Against: 7,433,237,535 votes
- Abstain: 5,832,047,971 votes
Following the meeting, the Board of Directors approved a specific reverse stock split ratio of 1-for-20. The Company intends to effect this split prior to December 31, 2022.
Outlook and Management Commentary
Management indicated an intention to file a Certificate of Amendment to implement the 1-for-20 reverse stock split before the end of 2022. The filing includes standard forward-looking statements regarding the timing and execution of the split, noting that actual results may differ from expectations.
Investor Verification Checklist
- Verify the final implementation date of the 1-for-20 reverse stock split via subsequent 8-K filings.
- Confirm the adjusted share count and trading symbol status on Nasdaq following the split.
- Review the definitive proxy statement filed on October 17, 2022, for detailed rationale behind the split.
- Monitor for any additional filings regarding the Certificate of Amendment.